Developing next generation anti-CD40 Ligand (CD40L) pathway antibodies


Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.

Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.

Read More

Our Strategy and Vision

Our strategy is to be focused, agile, driven, not cut corners, and guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) pathway antibodies for patients in need of potentially life-saving treatment options.

AT-1501 Clinical Development

Eledon is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four Phase 2 clinical studies in renal transplantation, islet cell transplantation, IgA Nephropathy, and amyotrophic lateral sclerosis (ALS).

Contact Us

Would you like more information about Eledon or subscribe to receive news updates automatically?

News & Events

Stay current on recent company announcements, clinical updates, and our conference presentations